Pembrolizumab trial reports no overall responses in thyroid cancer

ClinicalTrials.gov posted results on 9 September 2026 for a Phase 2 trial evaluating pembrolizumab in people with metastatic or locally advanced anaplastic or undifferentiated thyroid cancer. The single-arm study listed 0 participants for overall response rate in two reported measurements and recorded related adverse-event counts of 2 events, 5 events, 1 event, and 3 events.

Background

The trial evaluated pembrolizumab therapy in anaplastic thyroid cancer among patients with no curative alternative therapy. The record described pembrolizumab, also known as Keytruda, as the study intervention. Treatment was listed as pembrolizumab 200 mg given intravenously every three weeks until disease progression, treatment intolerance, withdrawal of consent, or death.

Trial design

This Phase 2, single-arm, open-label study was identified as NCT05119296 and enrolled 9 participants with thyroid cancer. The listed intervention was pembrolizumab. The study record’s overall status was active, not recruiting. Its stated purpose was to evaluate the activity of pembrolizumab in anaplastic thyroid cancer. No primary-outcome entries were supplied in the data.

Key results

The posted measurements listed an overall response rate of 0 participants for the pembrolizumab 200 mg group. The same overall response-rate value appeared twice in the reported measurements. The record also listed related adverse events as 2 events, 5 events, 1 event, and 3 events.

What this means

The available registry measurements did not show a listed overall response among the reported pembrolizumab group entries. Because the data block did not identify the timing, severity, or context of the adverse-event counts, these figures do not establish an overall safety profile. The small enrollment and single-arm design also limit direct comparison with another treatment.

Source

Source: ClinicalTrials.gov, posted trial results for the Phase 2 study of pembrolizumab in metastatic or locally advanced anaplastic or undifferentiated thyroid cancer, posted 9 September 2026. Available at clinicaltrials.gov/study/NCT05119296.